PHILADELPHIA, Dec. 12, 2013 /PRNewswire/ -- Expanse Bioinformatics is pleased to announce that it has obtained a new patent, US Patent 8,606,761, entitled "Lifestyle Optimization and Behavior Modification" which was issued from the United States Patent & Trademark Office on December 10th, 2013. The Expanse portfolio now numbers twenty four patents, which will serve as a foundation for a company offering personalized medicine products.
The patent covers technology for using genetic information in combination with behavioral information which could allow consumers to receive meaningful results regarding how they can minimize the risk for disease by modifying their lifestyle based on their genetics. Expanse's approach will provide real and meaningful answers to consumers on how to avoid disease through lifestyle modification and personalized treatment plans.
According to Dr. Charles Eldering, founder of Expanse Bioinformatics and a co-inventor of the technology, "The '761 patent represents a breakthrough in technology for providing specific recommendations for disease avoidance based on genetics, and avoids precisely the pitfalls plaguing 23andMe. The claimed technology is aimed at the types of criteria the FDA should consider requiring for companies wanting to provide genetic based health recommendations because it is based on statistically meaningful results, rather than weak correlations."
For more information regarding Expanse Bioinformatics contact Dr. Charles Eldering at email@example.com.
SOURCE Expanse Bioinformatics